Paterson David L, Rossi Flávia, Baquero Fernando, Hsueh Po-Ren, Woods Gail L, Satishchandran Vilas, Snyder Theresa A, Harvey Charlotte M, Teppler Hedy, Dinubile Mark J, Chow Joseph W
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
J Antimicrob Chemother. 2005 Jun;55(6):965-73. doi: 10.1093/jac/dki117. Epub 2005 Apr 22.
The SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance programme was begun in 2002 to monitor antimicrobial resistance trends among aerobic and facultative Gram-negative bacilli (GNB) isolated from intra-abdominal infections worldwide.
In 2003, 74 medical centres from 23 countries collected isolates for testing. Antimicrobial susceptibility testing was performed using broth microdilution according to the NCCLS guidelines for MIC testing.
A total of 5658 aerobic and facultative GNB were isolated from intra-abdominal infections. Enterobacteriaceae composed 84% of the total isolates. Among the agents tested, the carbapenems were the most consistently active against the Enterobacteriaceae. E. coli was the most common isolate (46%), and the susceptibility rate to the quinolone (70-90% susceptible), cephalosporin (80-97% susceptible), aminoglycoside (77-100% susceptible) and carbapenem (99-100% susceptible) agents tested varied among geographic regions, with isolates from the Asia/Pacific region generally being the most resistant. Extended-spectrum beta-lactamases (ESBLs) were detected phenotypically in 9% of E. coli, 14% of Klebsiella spp., and 14% of Enterobacter spp. worldwide. ESBL producers generally had a more antibiotic-resistant profile than non-ESBL producers.
Antimicrobial resistance among GNB isolated from intra-abdominal infections is a problem worldwide, especially in the Asia/Pacific region. The carbapenems ertapenem, meropenem and imipenem are highly active in vitro against Enterobacteriaceae isolated from intra-abdominal sites, including organisms that produce ESBLs.
SMART(监测抗菌药物耐药性趋势研究)监测项目始于2002年,旨在监测全球范围内从腹腔感染中分离出的需氧和兼性革兰氏阴性杆菌(GNB)的抗菌药物耐药性趋势。
2003年,来自23个国家的74个医疗中心收集分离株进行检测。根据NCCLS的MIC检测指南,采用肉汤微量稀释法进行抗菌药物敏感性试验。
共从腹腔感染中分离出5658株需氧和兼性GNB。肠杆菌科占分离株总数的84%。在所测试的药物中,碳青霉烯类对肠杆菌科的活性最为持久。大肠埃希菌是最常见的分离株(46%),对喹诺酮类(70 - 90%敏感)、头孢菌素类(80 - 97%敏感)、氨基糖苷类(77 - 100%敏感)和碳青霉烯类(99 - 100%敏感)药物的敏感率在不同地理区域有所不同,亚太地区的分离株通常耐药性最强。在全球范围内,9%的大肠埃希菌、14%的克雷伯菌属和14%的肠杆菌属通过表型检测出超广谱β-内酰胺酶(ESBLs)。产ESBLs菌株的耐药谱通常比非产ESBLs菌株更广。
从腹腔感染中分离出的GNB的抗菌药物耐药性是一个全球性问题,尤其是在亚太地区。碳青霉烯类药物厄他培南、美罗培南和亚胺培南在体外对从腹腔部位分离出的肠杆菌科细菌具有高度活性,包括产ESBLs的菌株。